Therapeutic Asset Ratings

131 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Nelitolimod Hormone Receptor Negative Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (50)
Nelitolimod Hormone Receptor Positive Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (50)
Nelitolimod TNBC - Triple-Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (49)
DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE) Myelodysplastic Syndromes	GCP-Service International West GmbH	P2	CCC (48)
Nl-Scn2A-002 Genetic Disease	University of California, San Diego	P1/2	CCC (48)
pp65 rna lp Recurrent High-grade Glioma	University of Florida	P1/2	CCC (48)
pp65 rna lp Recurrent Pulmonary Osteosarcoma	University of Florida	P1/2	CCC (48)
Aln-Pnp Genetic Risk Factor	Regeneron Pharmaceuticals	P1	CC (47)
Aln-Pnp Nonalcoholic Steatohepatitis (NASH)	Regeneron Pharmaceuticals	P1	CC (47)
Cpg-Odn Liver Metastasis Colon Cancer	University of Saskatchewan	P1/2	CC (47)
Nelitolimod Breast Neoplasms	QuantumLeap Healthcare Collaborative	P2	CC (46)
Nelitolimod HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (46)
Nelitolimod HER2-positive Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (46)
Tilsotolimod Solid Tumor	Idera Pharmaceuticals, Inc.	P2	CC (46)
Vidutolimod Non Small Cell Lung Cancer	Regeneron Pharmaceuticals	P2	CC (46)
DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-G-G-T-G-A-A-G-M5C-G-A-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC) Hepatitis B	GlaxoSmithKline	P1	CC (46)
Nelitolimod Intrahepatic Cholangiocarcinoma	TriSalus Life Sciences, Inc.	P1/2	CC (46)
Nl-Tard-001 Amyotrophic Lateral Sclerosis	n-Lorem Foundation	P1/2	CC (46)
Vidutolimod Basal Cell Carcinoma	Regeneron Pharmaceuticals	P2	CC (45)
Vidutolimod Clinical Stage III Cutaneous Melanoma AJCC v8	National Cancer Institute (NCI)	P2	CC (45)
Vidutolimod Cutaneous Squamous Cell Carcinoma	Regeneron Pharmaceuticals	P2	CC (45)
Vidutolimod Merkel Cell Carcinoma	Regeneron Pharmaceuticals	P2	CC (45)
Vidutolimod Metastatic Prostate Adenocarcinoma	Emory University	P2	CC (45)
Vidutolimod Oropharynx Squamous Cell Carcinoma	Regeneron Pharmaceuticals	P2	CC (45)
Vidutolimod Stage IV Prostate Cancer AJCC v8	Emory University	P2	CC (45)

Showing 51 to 75 of 131 assets

PreviousPage 3 of 6Next